Equity
€205,191 ▲ 0.9%
FORTILAB has made a profit without a break since 2019.
FORTILAB
Lifetime
20 annual accounts with figures on one time axispeak €98,594 (2025)
€98,594▲ 273%
lowest -€49,849 (2018)
€1,858▼ 31.9%
peak €214,366 (2016)
€205,191▲ 0.9%
€1.2m▲ 21.2%
peak 1.1 FTE (2017)
-not published
Board2 names since 2017
1 directorTIMMERMANS David
Owners
Documentsfilings and deeds
31-07-2026on the last day
2025micro format
Gross margin from €26,457 to €98,594Result from €2,729 to €1,858Change of role: TIMMERMANS David, from statutory manager to s… 09-10Debts from €976,880 to €1.2mCash from €19,404 to €10,141
Key points
from the 2025 annual accountsChecked score
90
Excellent
Financially stronger than 33% of micro companies in pharmaceuticals (NACE 21)
Probability in this band: under 0.55%
Bankruptcy probability within 12 months
0.1% Very low
0%0.5%1.5%4%10%≥ 25%
The dashed line is the sector median: 0.4% across 152 companies (NACE 21, micro).
About 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
12-2024: 0.5%
01-2025: 0.5%● unchanged vs 12-2024
02-2025: 0.5%● unchanged vs 01-2025
03-2025: 0.6%▲ +0.1 percentage points vs 02-2025
04-2025: 0.6%● unchanged vs 03-2025
05-2025: 0.6%● unchanged vs 04-2025
06-2025: 0.6%● unchanged vs 05-2025
07-2025: 0.8%▲ +0.2 percentage points vs 06-2025highest value
08-2025: 0.1%▼ -0.7 percentage points vs 07-2025lowest value
09-2025: 0.1%● unchanged vs 08-2025lowest value
10-2025: 0.1%● unchanged vs 09-2025lowest value
11-2025: 0.1%● unchanged vs 10-2025lowest value
12-2025: 0.1%● unchanged vs 11-2025lowest value
01-2026: 0.1%● unchanged vs 12-2025lowest value
02-2026: 0.1%● unchanged vs 01-2026
03-2026: 0.1%● unchanged vs 02-2026
04-2026: 0.1%● unchanged vs 03-2026
05-2026: 0.1%● unchanged vs 04-2026
06-2026: 0.1%● unchanged vs 05-2026
07-2026: 0.2%▲ +0.1 percentage points vs 06-2026
08-2026: 0.1%▼ -0.1 percentage points vs 07-2026
09-2026: 0.1%● unchanged vs 08-2026
10-2026: 0.1%● unchanged vs 09-2026
11-2026: 0.1%● unchanged vs 10-2026
Financial strengthWeak
Score breakdown
raises risk
Liquidity: current ratio 1.17, cash €10,141
lowers risk
Size: total assets €1.4m
Figures for financial year 2025 (filed on 31-07-2026)
Founded in 2005
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 21, micro). It does better than 37% of them on solvency, 5% on liquidity, 40% on profitability and 50% on growth.
The bankruptcy probability was computed on 10-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
The probability rests on the annual accounts with balance sheet date 31-12-2025.
Of the companies with a bankruptcy probability in the very low class on 30-06-2025, 0.1% went bankrupt within twelve months.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Comparable companies, two years later
In July 2024, 4,685 companies had the same profile as FORTILAB has now. Each dot stands for 12 companies, two years later.
97.0%
were still trading
1.9%
stopped another way
1.1%
went bankrupt
That fits the bankruptcy probability of FORTILAB itself: 0.1% within 12 months.
Test of the method
The method was tested on the 497,447 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 4,685 companies, not a prediction for FORTILAB. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit of up to €18,000 on 30-day terms is acceptable
Liquidity is tight, with a current ratio of 1.17 (1.21 in 2024), below the usual 1.5. Short-term debt is 85.2% and cash 0.7% of total assets. 85.2% of the assets are financed with debt and provisions.
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Five signals.
lowers riskraises riskneutral
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 31-07-2026, 0 days ahead of the deadline.
NBB · 10 filingsDeviation from the deadline
2025
on the day
2024
2 days early
2023
21 days late
2022
30 days late
2021
31 days late
2020
30 days late
2019
90 days late
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
The company filed its last 7 accounts on average 29 days after the deadline. In the sector (NACE 21), the median for financial year 2024 was 9 days before the deadline, and 32% of those companies filed late.
Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 22 August (5 of the last 5 accounts filed within 30 days either side of that date).
Companies Code · seven monthsWhere today falls in the filing period
10-11-2026 today31-12-2026 year end31-07-2027 deadline
Board and ownership
- DTPH INTERNATIONAL 20%equity €227,739 (2025) · 2025 annual accounts of DTPH INTERNATIONAL
Recent changes
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0877764579
Change of role: TIMMERMANS David, from statutory manager to sole director
General meeting of 11-09-2025 · Gazette deed
Registered office moved within Brussels
New registered office: Rue Colonel Van Gele, 120 1040 BRUXELLES · Previous registered office: Rue de l'Application 13 à 1160 Bruxelles · Board meeting of 01-07-2018 · Gazette deed
New manager
David TIMMERMANS appointed, Eric Wille resigned · Director discharge: Eric Wille · General meeting of 27-12-2017 · Gazette deed
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| FORTILAB Etterbeek | €1.4m | €98,594 | 14.8% | - |
| OROTECH Temse | €1.2m | €229,711 | 74.8% | 1.6 |
| Pharmacie de Vesnau Ittre | €1.2m | €262,582 | 33.2% | 3 |
| Axo Industry International Wavre | €1.6m | €293,358 | 57.6% | 3.9 |
| Laboratoires Biogam Forest | €2.7m | €145,607 | 72.6% | - |
| PHARMACIE SMITS Wavre | €1.9m | €373,639 | 14.0% | 8.2 |
| RevaTis Marche-en-Famenne | €4.1m | €136,602 | 62.0% | - |
These companies have the same main activity as FORTILAB: manufacture of basic pharmaceutical products and pharmaceutical preparations (NACE 21201). They are comparable in size and age: total assets between €1.2m and €4.1m, founded between 1981 and 2013.
Official details
Source: KBO- Status
- Active since 07-12-2005Normal situation
- Activity
- Manufacture of basic pharmaceutical products and pharmaceutical preparationsNACE 21201and 5 others
- Establishment unit
- 2.153.892.8191930 Zaventem, since 02-01-2006
- Financial year end
- 31 December
- Peppol
- Reachable since 19-11-2025
Annual accounts 2025
- ≈ €300,000estimated
- €1.4m▲ 17.7%
- ≈ 0.4 FTEestimated
- Filing
- Filed on 31-07-2026, on the last day of the filing period
Insights on FORTILAB
FORTILAB files the micro format. That format states no turnover. The gross margin rose from -€4,612 in 2006 to €98,594 in 2025.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about FORTILAB
- What is the company number of FORTILAB?
- The company number of FORTILAB is 0877.764.579. The VAT number is the same number with BE in front: BE 0877.764.579.
- Where is FORTILAB based?
- The registered office is at Kolonel Van Gelestraat 120, 1040 Etterbeek.Company details
- What does FORTILAB do?
- According to the KBO register, the main activity is manufacture of basic pharmaceutical products and pharmaceutical preparations (NACE 21201).
- What is the legal form of FORTILAB?
- FORTILAB is a private limited company (BV).
- When was FORTILAB founded?
- FORTILAB was founded on 07-12-2005.
- Is FORTILAB still active?
- Yes, FORTILAB is an active enterprise in the KBO register.
- How many employees does FORTILAB have?
- FORTILAB had an average of 0.2 full-time equivalents in financial year 2020, according to the filed annual accounts.Financials
- What is the turnover of FORTILAB?
- The turnover in financial year 2025 is ≈ €300,000. This figure is estimated from the gross margin of €98,594 and 2,667 comparable companies of the same size. It probably lies between €200,000 and €510,000. It is a rough estimate.
- Is FORTILAB profitable?
- In financial year 2025, FORTILAB made a profit of €1,858.
- Where can I find the annual accounts of FORTILAB?
- FORTILAB filed 20 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of FORTILAB due?
- FORTILAB must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark See what changed in the latest annual accounts.What changed
See how customers, suppliers and banks see your own company and what to improve first.